Mark L. Fuerst

Study suggests all adults age 18 and older should be screened for HCV. 

Shorter treatment could significantly reduce costs of therapy.

Effective direct-acting antivirals are available for teens.

Strong evidence supports removal of restrictions to direct-acting antiviral therapy based on recent drug use.

Two studies show these kidneys could be valuable resource for patients in need

New approaches are needed for physicians to engage young people who inject drugs

An urgent call to action to treat combined epidemics

Glucose tolerance is an independent predictor of overall mortality and hepatic decompensation in patients with HCV cirrhosis.

Ledipasvir/sofosbuvir is safe and effective for hepatitis C virus patients who fail on simeprevir/ sofosbuvir.

Real-world study shows efficacy of sofosbuvir/velpatasvir for 12 weeks

Treatment with a combination of ledipasvir and sofosbuvir can lead to large economic gains.

Clinicians need to carefully plan treatment when prescribing DAA therapy for patients infected with hepatitis C virus who have hepatocellular carcinoma.

All hepatitis C virus genotypes respond to therapy

Recipients of hepatitis C-infected kidneys treated with direct-acting antiviral agents are disease-free one year post-transplant.